tbuckley/cabot-search huggingface dataset:
The influence of tumor size, histological differentiation and smoking history in patients with completely resected stage I adenocarcinoma of the lung
Authors: M. Tsuboi, H. Kato, Y. Ichinose, M. Ohta, E. Hata, N. Tsubota, H. Tada, H. Wada, N. Hamajima, M. Ohta
Journal: Journal of Clinical Oncology (2006)

7197 Background: To test the hypothesis that patients with completely resected p-stage I adenocarcinoma [Ad.] of the lung contain a favorable subgroup of patients with well differentiated histology and tumor 2.0 cm or less in greatest dimension, we analyzed the results of the JLCRG trial (a randomized prospective trial of adjuvant chemotherapy with Uracil-Tegaful for stage I adenocarcinoma of the lung) by tumor size, smoking history, degree of histological differentiation and more. Methods: Patients were randomized to receive either oral uracil-tegaful (250 mg of tegaful /m 2 /day) for 2 years postoperatively or no adjuvant treatment. Multivariate analyses and interactions with the Cox proportional-hazards model were used to estimate the simultaneous effects of prognostic factors on survival. Results: The 5-year survival rate of the 412 patients with tumor 2cm or less in size was 89.8% (95% confidence interval [CI]: 86.8 to 92.8) versus 84.4% (95% CI: 81.3–87.4) for the 569 patients with tumor more than 2cm in size (median follow-up 72 months, p = 0.002). Although univariate analysis demonstrated improved survival for the patients with no smoking history and female gender, the selected covariates by multivariate analysis were as follows: age (hazard ratio [HR] for patients aged 70 years or more, 2.25; 95% CI: 1.58 to 3.14, p &lt; 0.0001), tumor size (HR for more than 2cm in size, 1.55; 95% CI: 1.10 to 2.21, p = 0.012), histological differentiation (HR for moderate and poor differentiation, 1.75, 95% CI: 1.25 to 2.47, p = 0.001), and treatment group (HR for the uracil-tegaful group, 0.68; 95% CI: 0.49 to 0.94, p = 0.02). For these prognostic factors, there was only one significant interaction between tumor size and the adjuvant treatment. Conclusions: 1) Patients with completely resected stage I Ad. of the lung contain a favorable subgroup of patients with aged less than 70 years, well differentiated histology, and a maximum tumor dimension of 2.0 cm or less. 2) Adjuvant chemotherapy with oral uracil-tegaful should also be considered for stage I Ad. patients more than 2 cm in tumor size. 3) 2cm in tumor size might be a good benchmark candidate of the description of T factor to facilitate treatment strategies and revisions of the TNM staging system. No significant financial relationships to disclose.
ステント内再狭窄病変遠位部に認めたsqueezingが再PCI(stent-in-stent)時,消失した1症例
Authors: 藤崎雅実, 弓野邦彦, 井上康憲, 中江佐八郎, 東吉志, 伊藤高史, 上原良樹, 日下雅文, 蓮田聡雄, 清水光行, 吉村道博
Journal: Circulation (2008)
LONG-TERM OUTCOME IN PATIENTS WITH COEXISTENT METABOLIC SYNDROME AND LONG-STANDING PERSISTENT ATRIAL FIBRILLATION UNDERGOING FIRST CATHETER ABLATION: RESULTS FROM A PROPENSITY-MATCHED POPULATION
Authors: Sanghamitra Mohanty, Chintan Trivedi, Domenico Della Rocca, Carola Gianni, Anu Salwan, Bryan Macdonald, Angel Mayedo, Alisara Anannab, John Burkhardt, Gerald Gallinghouse, Amin Al-Ahmad, Rodney Horton, Mohamed Bassiouny, Luigi Di Biase, Andrea Natale
Journal: Journal of the American College of Cardiology (2020)
Clinical activity of imatinib mesylate in combination with docetaxel in patients with advanced, platinum-resistant ovarian cancer—Hoosier Oncology Group GYN03–62
Authors: D. Matei, R. E. Emerson, N. Menning, J. Schilder, J. McClean, G. Sutton, D. Stephens, C. Whalen, L. Baldridge, D. Moore
Journal: Journal of Clinical Oncology (2006)

5091 Background: Ovarian tumors harborc-Kit and PDGF receptors. We showed in an in-vitro model that Imatinib (G) inhibits the growth of ovarian cancer cells. We hypothesized that G in combination with chemotherapy inhibits the growth of ovarian tumors. Data from a phase II clinical trial utilizing G in combination with Docetaxel (D) in patients with advanced ovarian cancer (OC) are presented. Methods: This was an open label, one stage, multi-center phase II clinical trial. Planned sample size was 23. Patients with relapsed, platinum-resistant or refractory OC expressing PDGFR or c-kit were eligible. PDGFR and c-kit expression was assessed prior to enrollment by IHC using archival tumor tissue. G was administered at 600mg/d continuously and D was given weekly (30mg/m 2 ) for 4 weeks, with 2 weeks break. Each cycle was 6 weeks, with a maximum of 6 cycles allowed. Tumor assessments were obtained after 2, 4 and 6 cycles. Response rate by RECIST was the primary endpoint. Results: 34 patients were screened. 17 tumors were c-kit + and 25 were PDGFRα +. 23 patients were enrolled. Of those, 4 patients had c-kit+/PDGFR- tumors, 12 were PDGFR+/c-kit- and 7 were c-kit+/PDGFR+. Median age was 55 (range 33–76) and median PS was 0 (range 0–2). Median number of prior treatments was 3 (range 1–9). Efficacy and toxicity data are available for 20 and 14 patients, respectively. Based on RECIST, there were 3 patients with PR and 3 patients with SD lasting at least 12 weeks. Of these 6 patients, 2 pts were c-kit+, 2 were PDGFR+ and 2 were PDGFR and c-kit+. All 6 patients had carboplatin and taxane resistant disease. Grade 3–4 toxicities were: neutropenia (2), thrombocytopenia (1), fatigue (1), dehydration (1), constipation (1), cardiac ischemia (1), nausea/vomiting (2), urinary frequency (1). Other G1–2 toxicities were: N/V (9), diarrhea (7), fatigue (8), mucositis (4), anemia (4), hypocalcemia (5), rash (6), anorexia (7), edema (5), hemolysis (1), non-neutropenic infections (7). Additional data will be available in May 2006. Conclusions: The combination G+D is tolerated well. Clinical activity consisted of 3 PRs (15% response rate) and 3 SD &gt; 3 months in pts with heavily pre-treated, platinum resistant OC expressing c-kit or PDGFRα. [Table: see text]
Diseases of the Gall-Bladder and Bile-Ducts, Including Gall-Stones.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy and safety of docetaxel-based chemotherapy in Japanese men over 80 years old with castration-resistant prostate cancer.
Authors: Takeo Kosaka, Yota Yasumizu, Ryuichi Mizuno, Akira Miyajima, Eiji Kikuchi, Morita Shinya, Hidaka Kono, Ken Nakagawa, Mototsugu Oya
Journal: Journal of Clinical Oncology (2013)

e16094 Background: Docetaxel-based chemotherapy is widely used to treat castration-resistant prostate cancer (CRPC). However, its efficacy in elderly males has not yet been fully elucidated. In Japan, the number of elderly CRPC patients continues to increase. Therefore, it is urgently necessary to evaluate the effect of docetaxel-based chemotherapy in elderly Japanese men with CRPC. Methods: Sixty-eight male patients with CRPC who were treated with first-line docetaxel-based chemotherapy in a single institution from 2006 to 2011 were evaluated retrospectively. Results: The median age was 72.4 ± 6.5 years. Ten patients (14.7 %) were ≥ 80 years old (older group), and 58 (85.3 %) were &lt; 80 years old (younger group). All patients received docetaxel at a dose of 75 mg/m 2 once every 3 weeks, and prednisolone 10 mg was given every day orally. The prostate-specific antigen (PSA) levels of the older and younger groups before docetaxel-based chemotherapy were 41.2 ± 37.4 ng/ml and 106.5 ± 184.7 ng/ml, respectively (P = 0.273). The PSA doubling times before docetaxel-based chemotherapy were 91.6 ± 92.6 days and 92.5 ± 91.9 days, respectively (P = 0.977). The performance status of the older group was 0 or 1. In the same group, 7 patients (70.0%) achieved a PSA decline of ≥ 30% and 4 patients (40.0%) achieved a PSA decline of ≥ 50%. In the younger group, the PSA decline was ≥ 30% in 37 patients (63.8%) and ≥ 50% in 26 patients (44.8%). The PSA decline rates of ≥ 30% and ≥ 50% were not significantly different between the two groups (p = 0.68 and p = 0.75, respectively). Progression-free survival (PFS) was also not significantly different between the two groups (PFS 5.3 vs. 7.3 months, p = 0.39). The major grade 3–4 toxicities were myelosuppression. Grade 3/4 neutropenia occurred in 80.0% of the older group and 78.0% of the younger group, and Grade 4 neutropenia occurred in 20.0% of the older group and 24.2% of the younger group. There were no significant differences between the two groups (Grade 3/4; p = 0.89, Grade 4; p = 0.79). Conclusions: Docetaxel-based chemotherapy showed a significant effect with a tolerable adverse event rate in elderly Japanese males over 80 years old with castration-resistant prostate cancer.
Next-generation sequencing to identify candidate gene for hereditary mixed polyposis syndrome.
Authors: Michele Caroline Gornick, Jun Li, Jishu Xu, Stephen B. Gruber
Journal: Journal of Clinical Oncology (2012)

1515 Background: Rare monogenic disorders are often due to mutations that are highly penetrant, extremely rare, and strongly disrupt normal biology. Hereditary mixed polyposis syndrome (HMPS, OMIM ID %601228), is characterized by a mixture of atypical juvenile polyps, hyperplasic polyps, sessile serrated adenomas and an increased risk of colorectal cancer. Polyps appear to be inherited in an autosomal dominant fashion. The putative susceptibility locus initially mapped to 15q13-14, however, the genetic basis of this syndrome is not well understood, and no mutation or associated variants have been identified. Methods: Germline DNA from four individuals from a family with clinically and pathologically confirmed HMPS was subjected to massively parallel sequencing (Illumina GAII). Affected individuals had an average of 30x coverage of their exome and 10x coverage of their genome. Sequence calls were filtered using the criteria of ≥ 4x coverage, quality score over depth ≤ 50, depth of coverage ≤ 360, allele balance ≤ 0.75, number or MAPQ zero reads at locus &lt; 4. Common variants were filtered out by excluding variants found in dbSNP (build131), 1000 Genomes Project, the Exome Variant Server or 80 unaffected controls sequenced by hybrid capture and whole exome sequencing. Polyphen2 and SIFT were used to predict pathogenicity of the novel, shared variants, and validated by Sanger sequencing. Expression levels of novel variants were examined in available tumor samples using qRT-PCR. Results: From the 32 previously unidentified nonsense, missense or splice site variants shared by the family members whose whole genomes were sequenced, only 5 (4 missense, 1 nonsense) were predicted to be damaging, leading to a small subset of novel candidate genes including ZNF426, which may be responsible for HMPS within this family. Conclusions: HMPS extremely difficult to accurately diagnosis and the genetic basis is unknown. Using next-generation sequencing we were able to detect previously unidentified low frequency allelic variants including a novel candidate locus.
MULTI-YEAR IMPROVEMENT IN AUTONOMIC TONE, BARORECEPTOR SENSITIVITY AND CARDIAC ELECTRICAL STABILITY USING VAGUS NERVE STIMULATION IN PATIENTS WITH HFREF IN THE ANTHEM-HF STUDY
Authors: Bruce David Nearing, Inderjit Anand, Imad Libbus, Lorenzo Dicarlo, Bruce Kenknight, Richard Verrier
Journal: Journal of the American College of Cardiology (2020)
Patient Perspectives on the Use of Artificial Intelligence
Authors: Carrie L. Kovarik
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Normal Functional Luminal Imaging Probe Panometry Findings Associate With Lack of Major Esophageal Motility Disorder on High-Resolution Manometry
Authors: Alexandra J. Baumann, Erica N. Donnan, Joseph R. Triggs, Wenjun Kou, Jacqueline Prescott, Alex Decorrevont, Emily Dorian, Peter J. Kahrilas, John E. Pandolfino, Dustin A. Carlson
Journal: Clinical Gastroenterology and Hepatology (2020)
Personal melanoma risk awareness versus intrinsic risk.
Authors: Caroline Robert, Céleste Lebbé, Sevrine Ricard, Philippe Saiag, Florent Grange, Laurent Mortier, Christine Lhomel, Bruno Sassolas
Journal: Journal of Clinical Oncology (2013)

9069 Background: Intrinsic risk factors for melanoma include personal and family history of the condition, a high number of naevi and a light skin phototype (I or II). The objective of this study was to evaluate the correlation between personal awareness of melanoma risk and objective risk factors and to analyze the elements associated with under-or over-evaluation of the actual risk. Methods: EDIFICE melanoma, a nationwide French observational survey, was conducted through phone interviews on a representative sample of 1502 subjects aged ≥ 18 using typical quotas. The survey took place from 28 th Sept 2011 to 20 th Oct 2011. Results: 393 subjects (26%) had at least one melanoma risk factor: personal: 1%; family history: 11%; high number of naevi: 8% and phototype I-II: 11%. 1109 (74%) had no risk factor. 1029 (73%) had a correct perception of their risk level, 135 (10%) overestimated their risk and 241 (17%) underestimated it. Compared to the control group (correct perception), the population overestimating the melanoma risk is characterised by a higher percentage of individuals living alone (32% vs. 24%, p&lt;0.05), socio-professional category + (38% vs. 28%, p&lt;0.01) and greater alcohol consumption (45% vs. 34%, p&lt;0.02). They are also more likely to expose themselves to the sun (89% vs. 78%, p&lt;0.004) and less likely to use sunscreen protection (58% vs. 44%, p&lt;0.003). A greater proportion of them participates in melanoma screening programmes (21% vs. 14%, p&lt;0.04). The population that underestimates the risk is characterised by lower educational attainment (11% vs. 7%, p&lt;0.05), greater use of high SPF sunscreen (41% vs. 29%, p&lt;0.0004) and a more frequent use of UV sunbeds (9% vs. 6%, p&lt;0.06). Conclusions: Overall, the French have a fair perception of their personal likelihood of developing melanoma. Interestingly, subjects overestimating their intrinsic risk do not behave appropriately with respect to sun protection measures (more sun exposure and less sunscreen protection). On the other hand, subjects underestimating their risk use UV sunbeds more extensively.
IMPACT OF BODY SIZE ON SURGICAL CORONARY REVASCULARIZATION FOR ISCHEMIC HEART FAILURE: INSIGHTS FROM STICHES
Authors: Nicholas Hendren, Lin Zhong, Ian Neeland, Katherine Michelis, Mark H. Drazner, Wai Hong Wilson Tang, Ambarish Pandey, Justin Lee Grodin
Journal: Journal of the American College of Cardiology (2020)
A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+ MBC): A trial of the Eastern Cooperative Oncology Group (E1105).
Authors: Carlos L. Arteaga, Ingrid A. Mayer, Anne M. O'Neill, Ramona F. Swaby, R. Katherine Alpaugh, Ximing J Yang, Lynne I. Wagner, Neal J. Meropol, Thomas James Saphner, Mohammad Jahanzeb, Edith A. Perez, Nancy U. Lin, George W. Sledge
Journal: Journal of Clinical Oncology (2012)

605 Background: Pre-clinical and nonrandomized clinical data support synergy of the combination of bevacizumab and trastuzumab. We conducted a randomized double-blinded phase III trial of chemotherapy/trastuzumab ± bevacizumab to evaluate efficacy (PFS after treatment initiation) of the addition of bevacizumab in first-line treatment of HER2+ MBC. Methods: Days 1, 8 and 15 paclitaxel ± carboplatin were administered with trastuzumab and either placebo or bevacizumab 10 mg/kg every 2 weeks for a total of 6 months. Antibody therapy was then continued without chemo every 3 weeks, until disease progression or unacceptable toxicity. Disease assessments were performed every 3 months. Results: Ninety-six of the planned 489 analyzable patients (pts) were accrued between 2007 and 2009, at which time the study terminated due to poor accrual. Seventy % of pts were post-menopausal, 60% had ER+/HER2+ BC. Median age was 55 years (28-80). Outcomes and toxicities are summarized on the tables below. Median follow-up was 30 months. Conclusions: The combination of chemotherapy, trastuzumab, and bevacizumab did not significantly increased toxicity, and was overall safe and well tolerated. No significant differences in clinical benefit were observed between both treatment arms. Data on CTCs and Quality of Life will be presented at the meeting. This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, MD, Chair) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA32291, CA31946, CA49957, CA27525, CA14548, CA17145, CA32102, CA25224, CA49. [Table: see text] [Table: see text]
RELATIONSHIP BETWEEN ADMISSION Q WAVES AND MICROVASCULAR INJURY IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION TREATED WITH PRIMARY PERCUTANEOUS CORONARY INTERVENTION
Authors: Christina Tiller, Martin Reindl, Magdalena Holzknecht, Lukas Innerhofer, Miriam Wagner, Ivan Lechner, Agnes Mayr, Gert Klug, Axel Bauer, Bernhard Metzler, Sebastian Reinstadler
Journal: Journal of the American College of Cardiology (2020)
Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL
Authors: Christian Winther Eskelund, Simon Husby, Francesco Favero, Tobias Wirenfeldt Klausen, Francisco German Rodriguez-Gonzalez, Arne Kolstad, Lone Bredo Pedersen, Riikka Katariina Räty, Christian H. Geisler, Mats Jerkeman, Joachim Weischenfeldt, Kirsten Grønbæk
Journal: Blood (2020)
Association Between the Proportion of Women on a Conference Planning Committee and the Proportion of Women Speakers at Medical Conferences
Authors: Kirstie C. Lithgow, Madalene Earp, Aleem Bharwani, Sarah Fletcher, Shannon M. Ruzycki
Journal: JAMA Network Open (2020)

This cross-sectional study examines the association of the proportion of women on a medical conference planning committee with the proportion of women speakers at the conference.
23andMe Develops First Drug Compound Using Consumer Data
Authors: Jennifer Abbasi
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The ERB family receptor dimerization in glioblastoma—An eTag assay analysis of 23 cases
Authors: M. R. Hameed, L. Sharer, E. Cho, S. Aisner, L. Cao, Y. Tan, A. Mukherjee, A. Chenna, S. Singh, C. Petropoulos
Journal: Journal of Clinical Oncology (2006)

1582 Background: Glioblastoma is the most malignant astrocytic tumor and accounts for about 50–60% of all astrocytic neoplasms. Despite intensive radiation and chemotherapy, less than 2% of patients survive more than 3 years. The Erb family of signaling molecules are transmembrane receptors with intrinsic kinase activity (except ErbB3) capable of modifying tyrosine residues on the receptor itself as well as on downstream signaling molecules. Under physiological conditions a variety of ligands interact and act as driving forces in the formation of homo and heterodimeric complexes between the four receptors leading to signal amplification and downstream activities. More than one third of glioblastoma cases show gene amplification of epidermal growth factor receptor (EGFR) which can be in truncated or rearranged form. The eTag assay system (Monogram) is an antibody based fluorescent assay that has the potential to assess the activation state of the EGFR signaling pathway. Methods: Twenty three cases of glioblastoma were selected for eTag analysis. There were twelve males and eleven females with ages ranging from 20–84 years. After reviewing the histology, 10 micron sections were cut from formalin fixed paraffin embedded (FFPE) tumor tissue blocks. Specific monoclonal antibodies of the Erb family bound to a fluorescent reporter (eTag) were applied to tissue sections. After binding of specific analyte, a second monoclonal antibody is added which acts as molecular scissors resulting in cleavage of “eTags”. The released eTag molecules are separated by capillary electrophoresis and measured as relative fluorescent units. Various FFPE tumor cell lines were used as controls. Results: Nineteen out of twenty three tumors (82%) showed the presence of dimers of the Erb family signaling pathway. High levels of intra and /or extracellular EGFR homodimers (HER-1-HER-1) were detected in eight samples (35%). EGFR-HER-3 dimers and EGFR-HER-2 dimers were seen at high levels in four and six samples (17% and 26% respectively). High levels of HER-2-HER3 dimers were detected in six samples (26%). Conclusion: The EGFR signaling pathway plays a substantial role in tumorigenesis of glioblastoma. Identification of receptor homo and heterodimers may be of value during treatment planning of individual patients. No significant financial relationships to disclose.